These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37974533)

  • 1. Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis.
    McGuinness CF; Black MA; Dunbier AK
    Cancer Med; 2023 Dec; 12(23):21545-21560. PubMed ID: 37974533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
    Swami N; Hwang WL; Guo JA; Hoffman H; Abramowitz MC; Elbakouny Z; Beltran H; Chipidza F; Choueiri T; Pra AD; Huang F; Kaochar S; Kantoff P; Kim DW; Kishan AU; Kobetz E; Marinac C; Mucci LA; Muralidhar V; Pollack A; Sanford NN; Schaeffer EM; Spratt DE; Zhao SG; Rebbeck TR; Nguyen PL; Feng FY; Mahal BA; Alshalalfa M
    Cancer Genet; 2021 Nov; 258-259():61-68. PubMed ID: 34551377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
    Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing panel-based tumor mutational burden (TMB) measurement.
    Budczies J; Allgäuer M; Litchfield K; Rempel E; Christopoulos P; Kazdal D; Endris V; Thomas M; Fröhling S; Peters S; Swanton C; Schirmacher P; Stenzinger A
    Ann Oncol; 2019 Sep; 30(9):1496-1506. PubMed ID: 31268125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
    Hu X; Guo J; Shi J; Li D; Li X; Zhao W
    BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.
    Li D; Wang D; Johann DJ; Hong H; Xu J
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
    Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
    Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity.
    Tan J; Egelston CA; Guo W; Stark JM; Lee PP
    EBioMedicine; 2024 Mar; 101():105035. PubMed ID: 38401418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
    Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMBur: a distributable tumor mutation burden approach for whole genome sequencing.
    Titmuss E; Corbett RD; Davidson S; Abbasi S; Williamson LM; Pleasance ED; Shlien A; Renouf DJ; Jones SJM; Laskin J; Marra MA
    BMC Med Genomics; 2022 Sep; 15(1):190. PubMed ID: 36071521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
    Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
    Front Oncol; 2022; 12():816706. PubMed ID: 35321431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
    Pan D; Hu AY; Antonia SJ; Li CY
    J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
    Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
    Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.